Sep 2026· International Neuropsychiatric Disease Journal· Vol 23, pp. 119-141· 0 citations
TL;DR
Two conclusions follow with reasonable confidence: the principal obstacle is not the absence of biological signal but the absence of demonstrated incremental clinical utility within a functioning delivery system, and evaluation frameworks that measure implementation outcomes alongside predictive performance are required before wider adoption can be justified.
Abstract
Precision psychiatry proposes that the combination of genomic, neuroimaging, peripheral biological, digital and health-record data will permit treatment to be matched to individual patients rather than to diagnostic categories. Opioid use disorder in the United States has been advanced repeatedly as a priority application, on the grounds that the condition is common, heterogeneous in course, associated with high mortality, and treated with a small number of medicines whose comparative effectiveness varies across individuals. Despite more than a decade of investment, no multimodal stratification tool is in routine use in American opioid use disorder care. This critical narrative review examines why. Literature was identified through structured searching of biomedical and open-access scholarly sources, supplemented by citation tracking and examination of authoritative institutional documents, with a final search date of 2 July 2026. Evidence was appraised for design adequacy, validation status, representativeness and relevance to implementation rather than merely to discovery. Five interacting classes of barrier are identified. The measurement layer remains immature: individual predictors from genomics, neuroimaging and digital sensing produce effect sizes that are reliable in aggregate but weak at the level of the individual patient. The modelling layer is dominated by retrospective, internally validated models with unstable outcome definitions and few prospective evaluations of clinical utility. The delivery layer is characterised by a segregated, under-resourced treatment system in which first-generation care is still not reliably delivered, so that stratified care is being proposed for a system that has not achieved coverage. The economic and regulatory layer offers no established route to reimbursement or oversight for multimodal decision tools. The equity layer carries a demonstrable risk that ancestry-limited genomic reference data and biased administrative training data will reproduce existing disparities in access. Two conclusions follow with reasonable confidence: the principal obstacle is not the absence of biological signal but the absence of demonstrated incremental clinical utility within a functioning delivery system, and evaluation frameworks that measure implementation outcomes alongside predictive performance are required before wider adoption can be justified.
The global landscape of opioid therapy presents a seemingly paradoxical duality: simultaneous over-use in high-income nations and under-access in low- and middle-income countries (LMICs). Despite decades of clinical experience and regulatory evolution, opioids remain among the most consequential, but controversial, dru...
F. Breve, Giustino Varrassi, Joseph V. Pergolizzi et al.· Advancements in Health Resea...· 0 citations
Background: The integration of Digital Therapeutics (DTx) into psychiatric care represents a paradigm shift in the management of anxiety and depression. With the continuous technological advancement of Software as a Medical Device (SaMD), its potential to alleviate shortages in psychiatric care is facing rigorous evalu...
Maryan Liasota, M. Kozłowska, K. Konopka et al.· International Journal of Inn...· 0 citations
Unhealthy alcohol use is often under-recognized in general medical care, but the transition from recognition to structured treatment remains inconsistent. Primary care is strategically positioned to identify risk patterns, distinguish screening from diagnosis, initiate brief interventions, assess withdrawal risk, and c...
Isabela Portes Campos, Luana Mendes da Silva, Gabriel Lino Martins Ferreira et al.· Revista de Estudos Interdisc...· 0 citations
BACKGROUND
As recognized members of the mental healthcare team, pharmacists are uniquely positioned to support use of prescription digital therapeutics (DTx) for schizophrenia. However, their specific role in care is yet to be clarified.
OBJECTIVES
To develop recommendations for how pharmacists can embed prescription...
Nathaniel M. Rickles, R. Patel, Smit Patel· Journal of the American Phar...· 0 citations
BACKGROUND
Day Treatment Programs (DTPs) provide intensive, multidisciplinary, non-residential care for adults with acute or complex mental illness. Despite their long-standing role as recovery-oriented alternatives to inpatient admission, contemporary DTPs vary widely in structure and therapeutic orientation.
AIMS
T...
Aurélie Montagne, J. Boruff, V. Paquin et al.· Journal of Mental Health· 0 citations
Psychiatric pharmacotherapy is among the most widely practiced and epistemically contested domains of contemporary medicine. Antidepressant consumption has risen significantly across OECD countries over the past decade, yet the neurobiological hypotheses used to justify these prescriptions remain unvalidated. This crit...